Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
BMC Cancer
Published in: BMC Cancer 1/2014

Open Access 01-12-2014 | Research article

RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer

Authors: Jin-Qiu Xue, Tian-Song Xia, Xiu-Qing Liang, Wenbin Zhou, Lin Cheng, Liang Shi, Ying Wang, Qiang Ding

Published in: BMC Cancer | Issue 1/2014

Login to get access

Abstract

Background

RNA binding proteins (RBPs) play a fundamental role in posttranscriptional control of gene expression. Different RBPs have oncogenic or tumor-suppressive functions on human cancers. RNPC1 belongs to the RNA recognition motif (RRM) family of RBPs, which could regulate expression of diverse targets by mRNA stability in human cancer cells. Several studies reported that RNPC1 played an important role in cancer, mostly acting as an oncogene or up-regulating in tumors. However, its role in human breast cancer remains unclear.

Methods

In the present study, we investigated the functional and mechanistic roles of RNPC1 in attenuating invasive signal including reverse epithelial-mesenchymal transition (EMT) to inhibit breast cancer cells aggressiveness in vitro. Moreover, RNPC1 suppress tumorigenicity in vivo. Further, we studied the expression of RNPC1 in breast cancer tissue and adjacent normal breast tissue by quantitative RT-PCR (qRT-PCR) and Western blot.

Results

We observed that RNPC1 expression was silenced in breast cancer cell lines compared to breast epithelial cells. More important, RNPC1 was frequently silenced in breast cancer tissue compared to adjacent normal breast tissue. Low RNPC1 mRNA expression was associated with higher clinical stages and mutp53, while low level of RNPC1 protein was associated with higher lymph node metastasis, mutp53 and lower progesterone receptor (PR). Functional assays showed ectopic expression of RNPC1 could inhibit breast tumor cell proliferation in vivo and in vitro through inducing cell cycle arrest, and further suppress tumor cell migration and invasion partly through repressing mutant p53 (mutp53) induced EMT.

Conclusions

Overall, our findings indicated that RNPC1 had a potential function to play a tumor-suppressor role which may be a potential marker in the therapeutic and prognostic of breast cancer.
Appendix
Available only for authorised users
Literature
1.
Smith RA, Cokkinides V, Brooks D, Saslow D, Brawley OW: Cancer screening in the United States, 2010 A Review of Current American Cancer Society Guidelines and Issues in Cancer Screening. CA Cancer J Clin. 2010, 60 (2): 99-119. 10.3322/caac.20063.CrossRefPubMed
2.
Siegel R, Naishadham D, Jemal A: Cancer statistics, 2013. CA Cancer J Clin. 2013, 63 (1): 11-30. 10.3322/caac.21166.CrossRefPubMed
3.
Feinberg AP, Tycko B: The history of cancer epigenetics. Nat Rev Cancer. 2004, 4 (2): 143-153. 10.1038/nrc1279.CrossRefPubMed
4.
Kim MY, Hur J, Jeong S: Emerging roles of RNA and RNA-binding protein network in cancer cells. BMB Rep. 2009, 42 (3): 125-130. 10.5483/BMBRep.2009.42.3.125.CrossRefPubMed
5.
Krecic AM, Swanson MS: hnRNP complexes: composition, structure, and function. Curr Opin Cell Biol. 1999, 11 (3): 363-371. 10.1016/S0955-0674(99)80051-9.CrossRefPubMed
6.
Dreyfuss G, Matunis MJ, Pinol-Roma S, Burd CG: hnRNP proteins and the biogenesis of mRNA. Annu Rev Biochem. 1993, 62: 289-321. 10.1146/annurev.bi.62.070193.001445.CrossRefPubMed
7.
Audic Y, Hartley RS: Post-transcriptional regulation in cancer. Biol Cell. 2004, 96 (7): 479-498. 10.1016/j.biolcel.2004.05.002.CrossRefPubMed
8.
Yisraeli JK: VICKZ proteins: a multi-talented family of regulatory RNA-binding proteins. Biol Cell. 2005, 97 (1): 87-96. 10.1042/BC20040151.CrossRefPubMed
9.
Li HJ, Watford W, Li CL, Parmelee A, Bryant MA, Deng CX, O'Shea J, Lee SB: Ewing sarcoma gene EWS is essential for meiosis and B lymphocyte development. J Clin Invest. 2007, 117 (5): 1314-1323. 10.1172/JCI31222.CrossRefPubMedPubMedCentral
10.
Sonenberg N, Hinnebusch AG: New modes of translational control in development, behavior, and disease. Mol Cell. 2007, 28 (5): 721-729. 10.1016/j.molcel.2007.11.018.CrossRefPubMed
11.
Shu L, Yan W, Chen X: RNPC1, an RNA-binding protein and a target of the p53 family, is required for maintaining the stability of the basal and stress-induced p21 transcript. Genes Dev. 2006, 20 (21): 2961-2972. 10.1101/gad.1463306.CrossRefPubMedPubMedCentral
12.
Yan W, Zhang J, Zhang Y, Jung YS, Chen X: p73 expression is regulated by RNPC1, a target of the p53 family, via mRNA stability. Mol Cell Biol. 2012, 32 (13): 2336-2348. 10.1128/MCB.00215-12.CrossRefPubMedPubMedCentral
13.
Cho SJ, Zhang J, Chen X: RNPC1 modulates the RNA-binding activity of, and cooperates with, HuR to regulate p21 mRNA stability. Nucleic Acids Res. 2010, 38 (7): 2256-2267. 10.1093/nar/gkp1229.CrossRefPubMedPubMedCentral
14.
Yin T, Cho SJ, Chen X: RNPC1, an RNA-binding protein and a p53 target, regulates macrophage inhibitory cytokine-1 (MIC-1) expression through mRNA stability. J Biol Chem. 2013, 288 (33): 23680-23686. 10.1074/jbc.M113.480186.CrossRefPubMedPubMedCentral
15.
Zhang J, Jun Cho S, Chen X: RNPC1, an RNA-binding protein and a target of the p53 family, regulates p63 expression through mRNA stability. Proc Natl Acad Sci U S A. 2010, 107 (21): 9614-9619. 10.1073/pnas.0912594107.CrossRefPubMedPubMedCentral
16.
Xu E, Zhang J, Chen X: MDM2 expression is repressed by the RNA-binding protein RNPC1 via mRNA stability. Oncogene. 2013, 32 (17): 2169-2178. 10.1038/onc.2012.238.CrossRefPubMed
17.
Zhang J, Cho SJ, Shu L, Yan W, Guerrero T, Kent M, Skorupski K, Chen H, Chen X: Translational repression of p53 by RNPC1, a p53 target overexpressed in lymphomas. Genes Dev. 2011, 25 (14): 1528-1543. 10.1101/gad.2069311.CrossRefPubMedPubMedCentral
18.
Miyamoto S, Hidaka K, Jin D, Morisaki T: RNA-binding proteins Rbm38 and Rbm24 regulate myogenic differentiation via p21-dependent and -independent regulatory pathways. Genes Cells. 2009, 14 (11): 1241-1252. 10.1111/j.1365-2443.2009.01347.x.CrossRefPubMed
19.
Zheng SL, Xu JF, Isaacs SD, Wiley K, Chang BL, Bleecker ER, Walsh PC, Trent JM, Meyers DA, Isaacs WB: Evidence for a prostate cancer linkage to chromosome 20 in 159 hereditary prostate cancer families. Hum Genet. 2001, 108 (5): 430-435. 10.1007/s004390100513.CrossRefPubMed
20.
Bar-Shira A, Pinthus JH, Rozovsky U, Goldstein M, Sellers WR, Yaron Y, Eshhar Z, Orr-Urtreger A: Multiple genes in human 20q13 chromosomal region are involved in an advanced prostate cancer xenograft. Cancer Res. 2002, 62 (23): 6803-6807.PubMed
21.
Tanner MM, Grenman S, Koul A, Johannsson O, Meltzer P, Pejovic T, Borg A, Isola JJ: Frequent amplification of chromosomal region 20q12-q13 in ovarian cancer. Genes Cells. 2000, 6 (5): 1833-1839.
22.
Korn WM, Yasutake T, Kuo WL, Warren RS, Collins C, Tomita M, Gray J, Waldman FM: Chromosome arm 20q gains and other genomic alterations in colorectal cancer metastatic to liver, as analyzed by comparative genomic hybridization and fluorescence in situ hybridization. Genes Chromosomes Cancer. 1999, 25 (2): 82-90. 10.1002/(SICI)1098-2264(199906)25:2<82::AID-GCC2>3.0.CO;2-6.CrossRefPubMed
23.
Knosel T, Schluns K, Stein U, Schwabe H, Schlag PM, Dietel M, Petersen I: Genetic imbalances with impact on survival in colorectal cancer patients. Histopathology. 2003, 43 (4): 323-331. 10.1046/j.1365-2559.2003.01720.x.CrossRefPubMed
24.
Krackhardt AM, Witzens M, Harig S, Hodi FS, Zauls AJ, Chessia M, Barrett P, Gribben JG: Identification of tumor-associated antigens in chronic lymphocytic leukemia by SEREX. Blood. 2002, 100 (6): 2123-2131. 10.1182/blood-2002-02-0513.CrossRefPubMed
25.
Carvalho B, Postma C, Mongera S, Hopmans E, Diskin S, van de Wiel MA, van Criekinge W, Thas O, Matthaei A, Cuesta MA, Droste JST, Craanen M, Schroeck E, Ylstra B, Meijer GA: Multiple putative oncogenes at the chromosome 20q amplicon contribute to colorectal adenoma to carcinoma progression. Gut. 2009, 58 (1): 79-89. 10.1136/gut.2007.143065.CrossRefPubMed
26.
Hotte GJ, Linam-Lennon N, Reynolds JV, Maher SG: Radiation sensitivity of esophageal adenocarcinoma: the contribution of the RNA-binding protein RNPC1 and p21-mediated cell cycle arrest to radioresistance. Radiat Res. 2012, 177 (3): 272-279. 10.1667/RR2776.1.CrossRefPubMed
27.
Ginestier C, Cervera N, Finetti P, Esteyries S, Esterni B, Adelaide J, Xerri L, Viens P, Jacquemier J, Charafe-Jauffret E, Chaffanet M, Birnbaum D, Bertucci F: Prognosis and gene expression profiling of 20q13-amplified breast cancers. Clin Cancer Res. 2006, 12 (15): 4533-4544. 10.1158/1078-0432.CCR-05-2339.CrossRefPubMed
28.
Letessier A, Sircoulomb F, Ginestier C, Cervera N, Monville F, Gelsi-Boyer V, Esterni B, Geneix J, Finetti P, Zemmour C, Viens P, Charafe-Jauffret E, Jacquemier J, Birnbaum D, Chaffanet M: Frequency, prognostic impact, and subtype association of 8p12, 8q24, 11q13, 12p13, 17q12, and 20q13 amplifications in breast cancers. BMC Cancer. 2006, 6 (1): 245-10.1186/1471-2407-6-245.CrossRefPubMedPubMedCentral
29.
Feldstein O, Ben-Hamo R, Bashari D, Efroni S, Ginsberg D: RBM38 is a direct transcriptional target of E2F1 that limits E2F1-induced proliferation. Mol Cancer Res. 2012, 10 (9): 1169-1177. 10.1158/1541-7786.MCR-12-0331.CrossRefPubMed
30.
Leveille N, Elkon R, Davalos V, Manoharan V, Hollingworth D, Oude Vrielink J, le Sage C, Melo CA, Horlings HM, Wesseling J, Ule J, Esteller M, Ramos A, Agami R: Selective inhibition of microRNA accessibility by RBM38 is required for p53 activity. Nat Commun. 2011, 2: 513-CrossRefPubMedPubMedCentral
31.
Zheng MJ, Wang J, Chen YW, Xu L, Xue DD, Fu W, Zhang YF, Du Q, Zhao Y, Ling LJ, Ding Q, Liu XA, Zha XM, Zheng W, Xia TS, Wang S: A novel mouse model of gastric cancer with human gastric microenvironment. Cancer Lett. 2012, 325 (1): 108-115. 10.1016/j.canlet.2012.06.011.CrossRefPubMed
32.
Pan H, Zhou W, He W, Liu X, Ding Q, Ling L, Zha X, Wang S: Genistein inhibits MDA-MB-231 triple-negative breast cancer cell growth by inhibiting NF-kappaB activity via the Notch-1 pathway. Int J Mol Med. 2012, 30 (2): 337-343.PubMed
33.
Colburn NH, Bruegge WF, Bates JR, Gray RH, Rossen JD, Kelsey WH, Shimada T: Correlation of anchorage-independent growth with tumorigenicity of chemically transformed mouse epidermal cells. Cancer Res. 1978, 38 (3): 624-634.PubMed
34.
Evan GI, Vousden KH: Proliferation, cell cycle and apoptosis in cancer. Nature. 2001, 411 (6835): 342-348. 10.1038/35077213.CrossRefPubMed
35.
Cho SJ, Jung YS, Zhang J, Chen X: The RNA-binding protein RNPC1 stabilizes the mRNA encoding the RNA-binding protein HuR and cooperates with HuR to suppress cell proliferation. J Biol Chem. 2012, 287 (18): 14535-14544. 10.1074/jbc.M111.326827.CrossRefPubMedPubMedCentral
36.
Stetler-Stevenson WG, Aznavoorian S, Liotta LA: Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993, 9: 541-573. 10.1146/annurev.cb.09.110193.002545.CrossRefPubMed
37.
Thiery JP, Sleeman JP: Complex networks orchestrate epithelial-mesenchymal transitions. Nat Rev Mol Cell Biol. 2006, 7 (2): 131-142. 10.1038/nrm1835.CrossRefPubMed
38.
Kang Y, Massague J: Epithelial-mesenchymal transitions: twist in development and metastasis. Cell. 2004, 118 (3): 277-279. 10.1016/j.cell.2004.07.011.CrossRefPubMed
39.
Simian M, Hirai Y, Navre M, Werb Z, Lochter A, Bissell MJ: The interplay of matrix metalloproteinases, morphogens and growth factors is necessary for branching of mammary epithelial cells. Development. 2001, 128 (16): 3117-3131.PubMedPubMedCentral
40.
41.
Brosh R, Rotter V: When mutants gain new powers: news from the mutant p53 field. Nat Rev Cancer. 2009, 9 (10): 701-713.PubMed
42.
Bartek J, Iggo R, Gannon J, Lane DP: Genetic and immunochemical analysis of mutant p53 in human breast cancer cell lines. Oncogene. 1990, 5 (6): 893-899.PubMed
43.
Maslon MM, Hupp TR: Drug discovery and mutant p53. Trends Cell Biol. 2010, 20 (9): 542-555. 10.1016/j.tcb.2010.06.005.CrossRefPubMed
44.
Wang SP, Wang WL, Chang YL, Wu CT, Chao YC, Kao SH, Yuan A, Lin CW, Yang SC, Chan WK, Li KC, Hong TM, Yang PC: p53 controls cancer cell invasion by inducing the MDM2-mediated degradation of Slug. Nat Cell Biol. 2009, 11 (6): 694-704. 10.1038/ncb1875.CrossRefPubMed
45.
Kogan-Sakin I, Tabach Y, Buganim Y, Molchadsky A, Solomon H, Madar S, Kamer I, Stambolsky P, Shelly A, Goldfinger N, Valsesia-Wittmann S, Puisieux A, Zundelevich A, Gal-Yam EN, Avivi C, Barshack I, Brait M, Sidransky D, Domany E, Rotter V: Mutant p53(R175H) upregulates Twist1 expression and promotes epithelial-mesenchymal transition in immortalized prostate cells. Cell Death Differ. 2011, 18 (2): 271-281. 10.1038/cdd.2010.94.CrossRefPubMed
Metadata
Title
RNA-binding protein RNPC1: acting as a tumor suppressor in breast cancer
Authors
Jin-Qiu Xue
Tian-Song Xia
Xiu-Qing Liang
Wenbin Zhou
Lin Cheng
Liang Shi
Ying Wang
Qiang Ding
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Cancer / Issue 1/2014
Electronic ISSN: 1471-2407
DOI
https://doi.org/10.1186/1471-2407-14-322

Other articles of this Issue 1/2014

BMC Cancer 1/2014 Go to the issue

Research article

Prevention and treatment of acute radiation-induced skin reactions: a systematic review and meta-analysis of randomized controlled trials

Research article

The inflammatory cytokine TNFα cooperates with Ras in elevating metastasis and turns WT-Ras to a tumor-promoting entity in MCF-7 cells

Research article

Expressions of MUC1 and vascular endothelial growth factor mRNA in blood are biomarkers for predicting efficacy of gefitinib treatment in non-small cell lung cancer

Research article

Decreased GATA5 mRNA expression associates with CpG island methylation and shortened recurrence-free survival in clear cell renal cell carcinoma

Debate

The biography of the immune system and the control of cancer: from St Peregrine to contemporary vaccination strategies

Research article

Prognostic models to predict overall and cause-specific survival for patients with middle ear cancer: a population-based analysis
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits